|
9th Annual Conference Of The British HIV Association [BHIVA]24 – 26 April 2003, University of Manchester
|
[AUTHOR(S):] BM Holden, N Mackie, J Clarke, J Walsh, L Greene and J Weber
St Mary's Hospital, London, UK
BHIVA Conf 2003 Apr 24-26;9:P2
BACKGROUND: BHIVA resistance testing guidelines were published in 2001.
OBJECTIVES: To examine compliance within our unit to BHIVA guidelines by determining (a) whether eligible patients were offered resistance testing and (b) whether resistance tests when performed were appropriate.
METHODS: (a) Retrospective audit of all patients with a viral load (VL) >50 copies/ml on highly active antiretroviral therapy (HAART) during January 2002; (b) retrospective audit of genotypic resistance tests performed January–May 2002.
RESULTS: (a) 112 patients had VL >50 copies/ml on HAART, most being persistently above this level. In five patients, this was the first or second detectable VL measurement following suppression to <50 copies/ml and resistance testing was performed in all. (b) 112 resistance tests were performed in 109 patients. 94 case notes were reviewed, identifying 10 seroconverters, six pregnant women and 75 treatment-experienced patients (three having duplicate tests). In the treatment-experienced group, 24 (32%) were on first-line therapy, 34 (45%) were on second-line therapy and the remaining 17 (23%) were heavily treatment-experienced. No chronically infected drug-naïve patients underwent resistance testing over the study period.
CONCLUSIONS: The use of resistance testing at St Mary's closely follows the BHIVA recommendations. The development of a local protocol will help ensure good practice continues.
PRESENTING AUTHOR: BM Holden
030424
P2
Copyright © 2003 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD